- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
14 result(s) found for: p300.
Displaying page 1 of 1.
EudraCT Number: 2018-001067-23 | Sponsor Protocol Number: PasHypo | Start Date*: 2018-05-07 | |||||||||||
Sponsor Name:Zealand University Hospital | |||||||||||||
Full Title: Pasireotide in the treatment of hypoglycemia following gastric bypass surgery | |||||||||||||
Medical condition: Postprandial reactive hypoglycemia in patients with prior Roux-en-Y gastric bypass surgery. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003134-42 | Sponsor Protocol Number: CELC200AUS15 | Start Date*: 2008-06-19 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 12-Week, Multi-center, Randomized, Prospective, Open-Label, Blinded Rater, Crossover Study of the Effects of Immediate-Release Carbidopa/Levodopa Versus Stalevo® on Markers of Event-Related Poten... | |||||||||||||
Medical condition: Idiopathic Parkinson’s disease and end-of-dose wearing off. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000285-10 | Sponsor Protocol Number: CCS1477-01 | Start Date*: 2021-06-08 |
Sponsor Name:CellCentric Ltd | ||
Full Title: An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination, in patients with advanced solid/metastatic tumours. | ||
Medical condition: Metastatic Castrate Resistant Prostate Cancer (mCRPC) and other advanced cancers with solid tumours. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-018273-38 | Sponsor Protocol Number: D1950C00011 | Start Date*: 2010-03-22 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effect of Single and Multiple Oral Doses of AZD1446/ Placebo and a Single Dos... | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000104-15 | Sponsor Protocol Number: CCS1477-02 | Start Date*: 2021-07-29 |
Sponsor Name:CellCentric Ltd | ||
Full Title: An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy in patients with advanced haematological malignancies. | ||
Medical condition: Acute Myeloid Leukaemia (AML)/high-risk Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Non-Hodgkin Lymphoma(NHL). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-002242-34 | Sponsor Protocol Number: BG14-04-2008 | Start Date*: 2008-07-10 | |||||||||||
Sponsor Name:Center for neuropsykiatrisk Schrizofreniforskning | |||||||||||||
Full Title: Antipsykotikas påvirkning af funktionelle kandidatendofænotyper for skizofreni: En prædiktor for outcome? | |||||||||||||
Medical condition: Skizofreni Interventioner rettet mod specifikke skizofrene endofænotyper vil gøre det muligt at knytte skizofrene patienters deficits til deres kliniske symptomer og behandlingens udfald. Således a... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011594-33 | Sponsor Protocol Number: SMRI-07TGF-1152 | Start Date*: 2009-11-02 | |||||||||||
Sponsor Name:LWL University Hospital Bochum, Ruhr-University Bochum | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled study of tetrabenazine as adjunctive therapy to risperidone in first-episode schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003049-13 | Sponsor Protocol Number: 7347 | Start Date*: 2022-08-24 |
Sponsor Name:Hôpitaux Universitaires de Strasbourg | ||
Full Title: EEG-MRI study of the effect of methylphenidate on neural mechanisms in adult patients with ADHD with or without mood disorders: A randomized controlled trial versus placebo. | ||
Medical condition: Attention Deficit Hyperactivity Disorder (ADHD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-004434-42 | Sponsor Protocol Number: BAY94-9027/15912 | Start Date*: 2013-04-15 | ||||||||||||||||
Sponsor Name:Bayer AG | ||||||||||||||||||
Full Title: A multi-center, phase III, non-controlled, open-label trial to evaluate the pharmacokinetics, safety, and efficacy of BAY 94-9027 for prophylaxis and treatment of bleeding in previously treated chi... | ||||||||||||||||||
Medical condition: severe hemophilia A (<1% FVIII:C) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male | |||||||||||||||||
Trial protocol: GB (Completed) BE (Completed) IT (Completed) NL (Completed) LT (Completed) BG (Completed) Outside EU/EEA PL (Completed) AT (Completed) NO (Ongoing) ES (Completed) GR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-001739-38 | Sponsor Protocol Number: TAK-831-2001 | Start Date*: 2017-09-19 | |||||||||||
Sponsor Name:Takeda Development Centre Europe Ltd. | |||||||||||||
Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate Pharmacodynamic Effects, Safety, Tolerability, and pharmacokinetics of Multiple Oral Doses of TAK-831 in Adult... | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024065-46 | Sponsor Protocol Number: 2010-379 | Start Date*: 2011-05-03 | |||||||||||||||||||||
Sponsor Name:Lone Baandrup | |||||||||||||||||||||||
Full Title: Melatonin vs. placebo til nedtrapning af benzodiazepiner hos patienter med skizofreni: et randomiseret klinisk forsøg (SMART) | |||||||||||||||||||||||
Medical condition: Patienter med kronisk skizofreni og i længerevarende behandling med en kombination af antipsykotika og benzodiazepiner. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-022364-12 | Sponsor Protocol Number: BAY86-5321/91745 | Start Date*: 2011-03-18 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A randomized, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macular edema | |||||||||||||
Medical condition: Diabetic macular edema with central involvement | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) CZ (Completed) ES (Completed) DK (Completed) IT (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004483-11 | Sponsor Protocol Number: 80-83600-98-40120 | Start Date*: 2016-07-08 | |||||||||||||||||||||
Sponsor Name:University Medical Center Utrecht | |||||||||||||||||||||||
Full Title: Raloxifene Augmentation in Patients with a Schizophrenia spectrum Disorder to reduce symptoms and improve cognition | |||||||||||||||||||||||
Medical condition: schizophrenia, schizoaffective, schizophreniform disorder or psychosis not otherwhise specified (DSM-IV 295.*) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) BE (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003952-29 | Sponsor Protocol Number: BAY63-2521/15681 | Start Date*: 2015-08-25 |
Sponsor Name:Bayer AG | ||
Full Title: Open-label, individual dose titration study to evaluate safety, tolerability and pharmacokinetics of riociguat in children from 6 to less than 18 years of age with pulmonary arterial hypertension (... | ||
Medical condition: Hypertension, Pulmonary | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: HU (Completed) IT (Trial now transitioned) GB (Completed) DE (Trial now transitioned) ES (Prematurely Ended) PL (Completed) Outside EU/EEA BE (Completed) RO (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
